UK markets close in 5 hours 29 minutes

Merus N.V. (MRUS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
13.79-0.41 (-2.89%)
At close: 04:00PM EST
13.79 0.00 (0.00%)
After hours: 04:28PM EST

Merus N.V.

Yalelaan 62
Utrecht 3584 CM
Netherlands
31 30 253 8800
https://www.merus.nl

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. Sven Ante Lundberg M.D.CEO, Pres, Principal Financial Officer & Exec. Director990.53kN/A1963
Mr. Peter B. Silverman J.D.Exec. VP, Gen. Counsel, Chief Intellectual Property Officer and Head of Utrecht & US Legal677.96kN/A1978
Mr. Hui Liu Ph.D.Chief Bus. Officer, Exec. VP & Head of Merus U.S.605.93kN/A1967
Dr. Hennie HoogenboomCo-Founder and Scientific AdvisorN/AN/AN/A
Harry ShumanChief Accounting OfficerN/AN/AN/A
Mr. Cornelis Adriaan de Kruif Ph.D.CTO & Exec. VPN/AN/A1965
Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.Chief Scientific Officer & Sr. VPN/AN/AN/A
Ms. Jillian ConnellVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Alexander Berthold Hendrik Bakker Ph.D.Chief Devel. Officer & Exec. VPN/AN/A1967
Dr. Andrew Joe M.D.Chief Medical Officer & Sr. VPN/AN/A1967
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Corporate governance

Merus N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.